DK2242771T3 - Bindingsmolekyler til den humane ox40-receptor - Google Patents
Bindingsmolekyler til den humane ox40-receptorInfo
- Publication number
- DK2242771T3 DK2242771T3 DK08862558.7T DK08862558T DK2242771T3 DK 2242771 T3 DK2242771 T3 DK 2242771T3 DK 08862558 T DK08862558 T DK 08862558T DK 2242771 T3 DK2242771 T3 DK 2242771T3
- Authority
- DK
- Denmark
- Prior art keywords
- receptor
- human
- binding molecules
- molecules
- binding
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1394707P | 2007-12-14 | 2007-12-14 | |
PCT/US2008/086417 WO2009079335A1 (en) | 2007-12-14 | 2008-12-11 | Binding molecules to the human ox40 receptor |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2242771T3 true DK2242771T3 (da) | 2013-08-26 |
Family
ID=40552119
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14191564.5T DK2851374T3 (da) | 2007-12-14 | 2008-12-11 | Bindingsmolekyler til den humane OX40-receptor |
DK08862558.7T DK2242771T3 (da) | 2007-12-14 | 2008-12-11 | Bindingsmolekyler til den humane ox40-receptor |
DK12195976.1T DK2594590T3 (da) | 2007-12-14 | 2008-12-11 | Fremgangsmåde til fremstilling af bindingsmolekyler til den humane OX40-receptor |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK14191564.5T DK2851374T3 (da) | 2007-12-14 | 2008-12-11 | Bindingsmolekyler til den humane OX40-receptor |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12195976.1T DK2594590T3 (da) | 2007-12-14 | 2008-12-11 | Fremgangsmåde til fremstilling af bindingsmolekyler til den humane OX40-receptor |
Country Status (29)
Country | Link |
---|---|
US (7) | US7960515B2 (da) |
EP (4) | EP2594590B1 (da) |
JP (4) | JP5761997B2 (da) |
KR (2) | KR20150061041A (da) |
CN (1) | CN101918447B (da) |
AR (2) | AR069681A1 (da) |
AU (1) | AU2008338591B8 (da) |
BR (1) | BRPI0820875B1 (da) |
CA (2) | CA2707773C (da) |
CL (1) | CL2008003706A1 (da) |
CO (1) | CO6280541A2 (da) |
DK (3) | DK2851374T3 (da) |
ES (3) | ES2526887T3 (da) |
HR (1) | HRP20141188T8 (da) |
HU (1) | HUE032735T2 (da) |
IL (3) | IL206297A (da) |
MX (1) | MX2010006466A (da) |
PA (1) | PA8807601A1 (da) |
PE (1) | PE20091269A1 (da) |
PH (1) | PH12015500806B1 (da) |
PL (2) | PL2594590T3 (da) |
PT (3) | PT2242771E (da) |
RU (1) | RU2010129045A (da) |
SG (2) | SG10201604770VA (da) |
SI (3) | SI2242771T1 (da) |
TW (1) | TW200932268A (da) |
UY (1) | UY31533A1 (da) |
WO (1) | WO2009079335A1 (da) |
ZA (1) | ZA201003579B (da) |
Families Citing this family (164)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2938527B2 (ja) * | 1990-07-30 | 1999-08-23 | 株式会社リコー | 自動原稿給送装置 |
ES2526887T3 (es) * | 2007-12-14 | 2015-01-16 | Bristol-Myers Squibb Company | Método para producir moléculas de unión al receptor OX40 humano |
PL2398498T3 (pl) | 2009-02-17 | 2019-03-29 | Ucb Biopharma Sprl | Cząsteczki przeciwciał swoiste wobec ludzkiego OX40 |
US20120020960A1 (en) * | 2010-07-26 | 2012-01-26 | Baylor Research Institute | Thymic Stromal Lymphopoietin (TSLP) and OX40 Ligand in Cancer |
CN103221427B (zh) * | 2010-08-23 | 2016-08-24 | 德克萨斯州立大学董事会 | 抗ox40抗体和使用其的方法 |
EP2614082B1 (en) | 2010-09-09 | 2018-10-03 | Pfizer Inc | 4-1bb binding molecules |
EA036047B1 (ru) * | 2011-07-11 | 2020-09-18 | Икнос Сайенсиз Са | Антитела, которые связываются с ox40, и их применение |
JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ox40抗体およびそれを使用する方法 |
GB201116092D0 (en) * | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
CN109369808B (zh) | 2012-08-24 | 2023-11-07 | 加利福尼亚大学董事会 | 用于治疗ror1癌症并抑制转移的抗体和疫苗 |
PT2925350T (pt) | 2012-12-03 | 2019-03-25 | Bristol Myers Squibb Co | Melhoria da atividade anticancerosa de proteínas de fusão de fc imunomoduladoras |
NZ712903A (en) * | 2013-03-18 | 2018-07-27 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
HRP20212023T1 (hr) | 2013-08-08 | 2022-04-01 | Cytune Pharma | Modulokini temeljeni na il-15 i il-15ralpha sushi domeni |
EP3527587A1 (en) | 2013-12-17 | 2019-08-21 | F. Hoffmann-La Roche AG | Combination therapy comprising ox40 binding agonists and pd-l1 binding antagonists |
KR102127408B1 (ko) * | 2014-01-29 | 2020-06-29 | 삼성전자주식회사 | 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체 |
LT3126394T (lt) * | 2014-03-31 | 2020-01-27 | F. Hoffmann-La Roche Ag | Antikūnai prieš ox40 ir jų naudojimo būdai |
MX2016012779A (es) * | 2014-03-31 | 2017-04-27 | Genentech Inc | Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40. |
CA2954056C (en) | 2014-07-11 | 2020-04-28 | Gilead Sciences, Inc. | Modulators of toll-like receptors for the treatment of hiv |
TW201619200A (zh) * | 2014-10-10 | 2016-06-01 | 麥迪紐有限責任公司 | 人類化抗-ox40抗體及其用途 |
EP3215850B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Assays for detecting t cell immune subsets and methods of use thereof |
EP3215637B1 (en) | 2014-11-03 | 2019-07-03 | F. Hoffmann-La Roche AG | Methods and biomarkers for predicting efficacy and valuation of an ox40 agonist treatment |
US20160152720A1 (en) | 2014-11-06 | 2016-06-02 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and tigit inhibitors |
SG10201807625PA (en) | 2014-11-17 | 2018-10-30 | Genentech Inc | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
SG10202003171TA (en) * | 2015-01-08 | 2020-05-28 | BioNTech SE | Agonistic tnf receptor binding agents |
MA41414A (fr) | 2015-01-28 | 2017-12-05 | Centre Nat Rech Scient | Protéines de liaison agonistes d' icos |
US10800846B2 (en) | 2015-02-26 | 2020-10-13 | Merck Patent Gmbh | PD-1/PD-L1 inhibitors for the treatment of cancer |
BR112017015880A2 (pt) | 2015-03-03 | 2018-07-31 | Kymab Ltd | anticorpos, usos e métodos |
MX2017012805A (es) | 2015-04-07 | 2018-04-11 | Genentech Inc | Complejo de unión a antígenos con actividad agonista y métodos de uso. |
EP3292152A1 (en) | 2015-05-07 | 2018-03-14 | Agenus Inc. | Anti-ox40 antibodies and methods of use thereof |
PE20180926A1 (es) | 2015-05-29 | 2018-06-08 | Bristol Myers Squibb Co | Anticuerpos contra el miembro 4 de la superfamilia del receptor del factor de necrosis tumoral (ox40) y sus usos |
GB201509338D0 (en) | 2015-05-29 | 2015-07-15 | Bergenbio As | Combination therapy |
WO2016205277A1 (en) | 2015-06-16 | 2016-12-22 | Merck Patent Gmbh | Pd-l1 antagonist combination treatments |
EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
US20180230431A1 (en) | 2015-08-07 | 2018-08-16 | Glaxosmithkline Intellectual Property Development Limited | Combination Therapy |
JP2018527366A (ja) | 2015-09-15 | 2018-09-20 | ギリアード サイエンシーズ, インコーポレイテッド | HIVを処置するためのtoll様レセプターのモジュレーター |
US20190022092A1 (en) | 2015-09-15 | 2019-01-24 | Acerta Pharma B.V. | Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist |
MA43017A (fr) | 2015-10-02 | 2018-08-08 | Hoffmann La Roche | Anticorps bispécifiques spécifiques d'un récepteur de co-stimulation du tnf |
EP3363816A4 (en) * | 2015-10-15 | 2019-10-09 | Dingfu Biotarget Co., Ltd. | ANTI-OX40 ANTIBODIES AND USES THEREOF |
AU2016348391A1 (en) | 2015-11-03 | 2018-05-17 | Janssen Biotech, Inc. | Antibodies specifically binding TIM-3 and their uses |
JP2019505476A (ja) | 2015-12-01 | 2019-02-28 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited | 組合せ処置およびその方法 |
JP7089470B2 (ja) * | 2015-12-02 | 2022-06-22 | アジェナス インコーポレイテッド | 抗体およびその使用方法 |
RU2722019C2 (ru) | 2015-12-03 | 2020-05-26 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Циклические пуриновые динуклеотиды в качестве модуляторов sting |
WO2017098421A1 (en) | 2015-12-08 | 2017-06-15 | Glaxosmithkline Intellectual Property Development Limited | Benzothiadiazine compounds |
AU2017211540B2 (en) | 2016-01-25 | 2020-04-30 | Pfizer Inc. | Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer |
WO2017153952A1 (en) | 2016-03-10 | 2017-09-14 | Glaxosmithkline Intellectual Property Development Limited | 5-sulfamoyl-2-hydroxybenzamide derivatives |
IL295649A (en) | 2016-04-07 | 2022-10-01 | Glaxosmithkline Ip Dev Ltd | Heterocyclic amides are useful as protein modulators |
RU2018137389A (ru) | 2016-04-07 | 2020-05-12 | Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Гетероциклические амиды, полезные в качестве модуляторов |
US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
US11299751B2 (en) | 2016-04-29 | 2022-04-12 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
PE20190106A1 (es) | 2016-05-05 | 2019-01-15 | Glaxosmithkline Ip No 2 Ltd | Inhibidores del potenciador del homologo zeste 2 |
IL299099A (en) | 2016-06-27 | 2023-02-01 | Univ California | Combinations of cancer treatments |
CA3031082C (en) * | 2016-07-19 | 2023-08-22 | Ibentrus, Inc. | Bispecific proteins and methods for preparing same |
GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
EP3487503A1 (en) | 2016-07-20 | 2019-05-29 | GlaxoSmithKline Intellectual Property Development Limited | Isoquinoline derivatives as perk inhibitors |
EP3494140A1 (en) | 2016-08-04 | 2019-06-12 | GlaxoSmithKline Intellectual Property Development Ltd | Anti-icos and anti-pd-1 antibody combination therapy |
JP2019530434A (ja) | 2016-08-05 | 2019-10-24 | ジェネンテック, インコーポレイテッド | アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法 |
CA3033665A1 (en) | 2016-08-12 | 2018-02-15 | Janssen Biotech, Inc. | Fc engineered anti-tnfr superfamily member antibodies having enhanced agonistic activity and methods of using them |
CN109863170A (zh) | 2016-08-12 | 2019-06-07 | 詹森生物科技公司 | 具有增强的激动作用和效应子功能的工程化抗体及其他含Fc结构域分子 |
JP6644956B2 (ja) * | 2016-09-07 | 2020-02-12 | サクシン ライフサイエンシス ピーヴィーティー エルティディーSaksin Lifesciences Pvt Ltd | Vegfに対する合成の抗体およびそれらの使用 |
IL265762B2 (en) | 2016-10-06 | 2024-04-01 | Merck Patent Gmbh | Dosing regimen of avolumab for cancer treatment |
TWI788307B (zh) | 2016-10-31 | 2023-01-01 | 美商艾歐凡斯生物治療公司 | 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞 |
EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
EP3538152A4 (en) | 2016-11-09 | 2020-09-30 | Agenus Inc. | ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF |
KR20190090823A (ko) | 2016-12-01 | 2019-08-02 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | 조합 요법 |
BR112019011370A2 (pt) | 2016-12-01 | 2019-10-15 | Glaxosmithkline Ip Dev Ltd | terapia de combinação |
CA3045940A1 (en) | 2016-12-15 | 2018-06-21 | Abbvie Biotherapeutics Inc. | Anti-ox40 antibodies and their uses |
AU2017384528A1 (en) | 2016-12-19 | 2019-07-04 | Ichnos Sciences SA | Novel TNFR agonists and uses thereof |
US20200121719A1 (en) | 2017-01-06 | 2020-04-23 | Iovance Biotherapeutics, Inc. | Expansion of tumor infiltrating lymphocytes (tils) with tumor necrosis factor receptor superfamily (tnfrsf) agonists and therapeutic combinations of tils and tnfrsf agonists |
BR112019017738A2 (pt) | 2017-02-27 | 2020-04-07 | Glaxosmithkline Ip Dev Ltd | combinação, composição farmacêutica, uso de uma combinação ou composição farmacêutica, método para tratar câncer em um humano, e, composto |
CN108623686A (zh) * | 2017-03-25 | 2018-10-09 | 信达生物制药(苏州)有限公司 | 抗ox40抗体及其用途 |
US11819517B2 (en) | 2017-06-05 | 2023-11-21 | Iovance Biotherapeutics, Inc. | Methods of using tumor infiltrating lymphocytes in double-refractory melanoma |
US20200190195A1 (en) | 2017-06-09 | 2020-06-18 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
US20200181275A1 (en) | 2017-06-09 | 2020-06-11 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy with icos agonist and ox40 agonist to treat cancer |
WO2019021208A1 (en) | 2017-07-27 | 2019-01-31 | Glaxosmithkline Intellectual Property Development Limited | USEFUL INDAZOLE DERIVATIVES AS PERK INHIBITORS |
CN111511762A (zh) | 2017-08-21 | 2020-08-07 | 天演药业公司 | 抗cd137分子及其用途 |
EP3672634A1 (en) * | 2017-08-24 | 2020-07-01 | Invenra, Inc. | Multivalent receptor-clustering agonist antibody constructs |
CA3073953A1 (en) | 2017-08-31 | 2019-03-07 | Io Therapeutics, Inc. | Rar selective agonists in combination with immune modulators for cancer immunotherapy |
WO2019053617A1 (en) | 2017-09-12 | 2019-03-21 | Glaxosmithkline Intellectual Property Development Limited | CHEMICAL COMPOUNDS |
CA3077337A1 (en) | 2017-10-05 | 2019-04-11 | Glaxosmithkline Intellectual Property Development Limited | Modulators of stimulator of interferon genes (sting) |
TW201927771A (zh) | 2017-10-05 | 2019-07-16 | 英商葛蘭素史密斯克藍智慧財產發展有限公司 | 可作為蛋白質調節劑之雜環醯胺及其使用方法 |
CN111601883A (zh) | 2017-11-17 | 2020-08-28 | 艾欧凡斯生物治疗公司 | 由细针抽吸物和小活检物扩增til |
JP7479281B2 (ja) * | 2017-11-24 | 2024-05-08 | ユーキュア・(ベイジン)・バイオファーマ・カンパニー・リミテッド | 抗ox40抗体及びその用途 |
US11142579B2 (en) | 2017-12-06 | 2021-10-12 | Sorrento Therapeutics, Inc. | Variant antibodies that bind OX40 |
ES2966569T3 (es) | 2017-12-29 | 2024-04-23 | Ap Biosciences Inc | Proteínas monoespecíficas y biespecíficas con regulación de puntos de control inmunitario para la terapia del cáncer |
BR112020013848A2 (pt) | 2018-01-08 | 2020-12-01 | Iovance Biotherapeutics, Inc. | métodos para expandir linfócitos infiltrantes de tumor e para tratar um indivíduo com câncer, população de linfócitos infiltrantes de tumor, e, método para avaliar fatores de transcrição |
WO2019136459A1 (en) | 2018-01-08 | 2019-07-11 | Iovance Biotherapeutics, Inc. | Processes for generating til products enriched for tumor antigen-specific t-cells |
US11713446B2 (en) | 2018-01-08 | 2023-08-01 | Iovance Biotherapeutics, Inc. | Processes for generating TIL products enriched for tumor antigen-specific T-cells |
WO2019148445A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Precision/context-dependent activatable antibodies, and methods of making and using the same |
WO2019148444A1 (en) | 2018-02-02 | 2019-08-08 | Adagene Inc. | Anti-ctla4 antibodies and methods of making and using the same |
JP2021512962A (ja) | 2018-02-13 | 2021-05-20 | アイオバンス バイオセラピューティクス,インコーポレイテッド | アデノシンa2a受容体アンタゴニストによる腫瘍浸潤性リンパ球(til)の拡大培養並びにtil及びアデノシンa2a受容体アンタゴニストの治療的組み合わせ |
CA3098303A1 (en) | 2018-04-27 | 2019-10-31 | Iovance Biotherapeutics, Inc. | Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3103040A1 (en) * | 2018-05-11 | 2019-11-14 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing same, and use thereof |
GB201807924D0 (en) | 2018-05-16 | 2018-06-27 | Ctxt Pty Ltd | Compounds |
TWI793325B (zh) | 2018-05-23 | 2023-02-21 | 美商輝瑞大藥廠 | 對cd3具特異性之抗體及其用途 |
TWI816396B (zh) | 2018-05-23 | 2023-09-21 | 美商輝瑞大藥廠 | 特異性針對gucy2c之抗體及其用途 |
GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
GB201811404D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-CD137 Antibodies |
CN112424229A (zh) | 2018-07-12 | 2021-02-26 | F星贝塔有限公司 | 结合cd137和ox40的抗体分子 |
US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
TW202031273A (zh) | 2018-08-31 | 2020-09-01 | 美商艾歐凡斯生物治療公司 | 抗pd-1抗體難治療性之非小細胞肺癌(nsclc)病患的治療 |
KR20210064269A (ko) | 2018-09-20 | 2021-06-02 | 이오반스 바이오테라퓨틱스, 인크. | 동결보존된 종양 샘플로부터의 til의 확장 |
EP3876957A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients refractory for anti-pd-1 antibody |
MX2021004953A (es) | 2018-11-05 | 2021-08-11 | Iovance Biotherapeutics Inc | Seleccion de celulas t reactivas al tumor mejoradas. |
EP3877511A1 (en) | 2018-11-05 | 2021-09-15 | Iovance Biotherapeutics, Inc. | Expansion of tils utilizing akt pathway inhibitors |
KR20210091213A (ko) | 2018-11-05 | 2021-07-21 | 이오반스 바이오테라퓨틱스, 인크. | 종양 침윤 림프구의 생성 방법 및 면역치료법에서 이의 용도 |
MX2021005377A (es) * | 2018-11-09 | 2021-09-14 | Beth Israel Deaconess Medical Ct Inc | Terapias dirigidas a cdcp1. |
CA3123392A1 (en) | 2018-12-19 | 2020-06-25 | Iovance Biotherapeutics, Inc. | Methods of expanding tumor infiltrating lymphocytes using engineered cytokine receptor pairs and uses thereof |
WO2020128893A1 (en) | 2018-12-21 | 2020-06-25 | Pfizer Inc. | Combination treatments of cancer comprising a tlr agonist |
JP2022524921A (ja) | 2019-02-01 | 2022-05-11 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | がんを治療するための、ペムブロリズマブと組み合わせたベランタマブマフォドチン |
WO2020205662A1 (en) | 2019-03-29 | 2020-10-08 | Myst Therapeutics, Inc. | Ex vivo methods for producing a t cell therapeutic and related compositions and methods |
US20220249559A1 (en) | 2019-05-13 | 2022-08-11 | Iovance Biotherapeutics, Inc. | Methods and compositions for selecting tumor infiltrating lymphocytes and uses of the same in immunotherapy |
US20230053328A9 (en) | 2019-05-24 | 2023-02-16 | Pfizer Inc. | Combination therapies using cdk inhibitors |
WO2020239558A1 (en) | 2019-05-24 | 2020-12-03 | Pfizer Inc. | Combination therapies using cdk inhibitors |
CN110172090B (zh) * | 2019-06-03 | 2020-04-03 | 中山标佳生物科技有限公司 | Cd134单克隆抗体及其制备方法和癌症治疗中的应用 |
WO2020261097A1 (en) | 2019-06-26 | 2020-12-30 | Glaxosmithkline Intellectual Property Development Limited | Il1rap binding proteins |
US11339159B2 (en) | 2019-07-17 | 2022-05-24 | Pfizer Inc. | Toll-like receptor agonists |
GB201910304D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
GB201910305D0 (en) | 2019-07-18 | 2019-09-04 | Ctxt Pty Ltd | Compounds |
WO2021043961A1 (en) | 2019-09-06 | 2021-03-11 | Glaxosmithkline Intellectual Property Development Limited | Dosing regimen for the treatment of cancer with an anti icos agonistic antibody and chemotherapy |
CN114729049A (zh) | 2019-09-27 | 2022-07-08 | 葛兰素史密斯克莱知识产权发展有限公司 | 抗原结合蛋白 |
CA3155727A1 (en) | 2019-10-25 | 2021-04-29 | Cecile Chartier-Courtaud | Gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
US20230032934A1 (en) | 2019-11-27 | 2023-02-02 | Myst Therapeutics, Llc | Method of producing tumor-reactive t cell composition using modulatory agents |
EP4073236A1 (en) | 2019-12-11 | 2022-10-19 | Iovance Biotherapeutics, Inc. | Processes for the production of tumor infiltrating lymphocytes (tils) and methods of using the same |
WO2021124073A1 (en) | 2019-12-17 | 2021-06-24 | Pfizer Inc. | Antibodies specific for cd47, pd-l1, and uses thereof |
MX2022007643A (es) | 2019-12-18 | 2022-07-19 | Pfizer | Regimen de tratamiento del cancer una vez por dia con un inhibidor de prmt5. |
EP4096718A1 (en) | 2020-01-28 | 2022-12-07 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
WO2021174208A1 (en) | 2020-02-27 | 2021-09-02 | Myst Therapeutics, Llc | Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof |
CA3174908A1 (en) | 2020-03-09 | 2021-09-16 | Pfizer Inc. | Fusion proteins and uses thereof |
US20230139700A1 (en) | 2020-03-23 | 2023-05-04 | Bio-Thera Solutions, Ltd. | Development and application of immune cell activator |
WO2021191865A1 (en) * | 2020-03-26 | 2021-09-30 | Dusa Pharmaceuticals, Inc. | Management of dermal neurofibromatosis lesions |
JP2023523855A (ja) | 2020-05-04 | 2023-06-07 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球の製造方法及び免疫療法におけるその使用 |
US20230293685A1 (en) | 2020-05-04 | 2023-09-21 | Iovance Biotherapeutics, Inc. | Selection of improved tumor reactive t-cells |
EP4149975A2 (en) | 2020-05-13 | 2023-03-22 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
AU2021308586A1 (en) | 2020-07-17 | 2023-03-02 | Pfizer Inc. | Therapeutic antibodies and their uses |
EP4211167A1 (en) | 2020-09-14 | 2023-07-19 | Pfizer Inc. | Methods, therapies and uses for treating cancer |
EP4225330A1 (en) | 2020-10-06 | 2023-08-16 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
WO2022076606A1 (en) | 2020-10-06 | 2022-04-14 | Iovance Biotherapeutics, Inc. | Treatment of nsclc patients with tumor infiltrating lymphocyte therapies |
CN114515335A (zh) | 2020-11-19 | 2022-05-20 | 百奥泰生物制药股份有限公司 | 抗ox40抗体在***或癌症中的应用 |
WO2022118197A1 (en) | 2020-12-02 | 2022-06-09 | Pfizer Inc. | Time to resolution of axitinib-related adverse events |
US20240131064A1 (en) | 2020-12-11 | 2024-04-25 | Iovance Biotherapeutics, Inc. | Treatment of cancer patients with tumor infiltrating lymphocyte therapies in combination with braf inhibitors and/or mek inhibitors |
WO2022130206A1 (en) | 2020-12-16 | 2022-06-23 | Pfizer Inc. | TGFβr1 INHIBITOR COMBINATION THERAPIES |
EP4262811A1 (en) | 2020-12-17 | 2023-10-25 | Iovance Biotherapeutics, Inc. | Treatment with tumor infiltrating lymphocyte therapies in combination with ctla-4 and pd-1 inhibitors |
JP2024500403A (ja) | 2020-12-17 | 2024-01-09 | アイオバンス バイオセラピューティクス,インコーポレイテッド | 腫瘍浸潤リンパ球によるがんの治療 |
WO2022153161A1 (en) | 2021-01-14 | 2022-07-21 | Pfizer Inc. | Treatment of cancer using a prmt5 inhibitor |
EP4288140A1 (en) | 2021-02-05 | 2023-12-13 | Iovance Biotherapeutics, Inc. | Adjuvant therapy for cancer |
BR112023017296A2 (pt) | 2021-03-02 | 2023-11-14 | Glaxosmithkline Ip Dev Ltd | Piridinas substituídas como inibidores de dnmt1 |
WO2022198055A1 (en) * | 2021-03-19 | 2022-09-22 | KSQ Therapeutics, Inc. | Uses of antagonist, non-depleting ox40 antibodies |
US20240166747A1 (en) | 2021-03-31 | 2024-05-23 | Glazosmithkline Intellectual Property Development Limited | Antigen binding proteins and combinations thereof |
BR112023021665A2 (pt) | 2021-04-19 | 2023-12-19 | Iovance Biotherapeutics Inc | Método para tratar um câncer, e, composição |
CA3219148A1 (en) | 2021-05-17 | 2022-11-24 | Frederick G. Vogt | Pd-1 gene-edited tumor infiltrating lymphocytes and uses of same in immunotherapy |
TW202327631A (zh) | 2021-07-28 | 2023-07-16 | 美商艾歐凡斯生物治療公司 | 利用腫瘤浸潤性淋巴球療法與kras抑制劑組合治療癌症患者 |
CA3232700A1 (en) | 2021-09-24 | 2023-03-30 | Rafael CUBAS | Expansion processes and agents for tumor infiltrating lymphocytes |
AR127482A1 (es) | 2021-10-27 | 2024-01-31 | Iovance Biotherapeutics Inc | Sistemas y métodos para coordinar la fabricación de células para inmunoterapia específica de paciente |
WO2023086803A1 (en) | 2021-11-10 | 2023-05-19 | Iovance Biotherapeutics, Inc. | Methods of expansion treatment utilizing cd8 tumor infiltrating lymphocytes |
WO2023147486A1 (en) | 2022-01-28 | 2023-08-03 | Iovance Biotherapeutics, Inc. | Tumor infiltrating lymphocytes engineered to express payloads |
WO2023201369A1 (en) | 2022-04-15 | 2023-10-19 | Iovance Biotherapeutics, Inc. | Til expansion processes using specific cytokine combinations and/or akti treatment |
WO2023218320A1 (en) | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
WO2023242769A1 (en) | 2022-06-17 | 2023-12-21 | Pfizer Inc. | Il-12 variants, anti-pd1 antibodies, fusion proteins, and uses thereof |
WO2024003773A1 (en) | 2022-07-01 | 2024-01-04 | Pfizer Inc. | 2,7-naphthyridine compounds as mastl inhibitors |
WO2024009191A1 (en) | 2022-07-05 | 2024-01-11 | Pfizer Inc. | Pyrido[4,3-d]pyrimidine compounds |
WO2024030758A1 (en) | 2022-08-01 | 2024-02-08 | Iovance Biotherapeutics, Inc. | Chimeric costimulatory receptors, chemokine receptors, and the use of same in cellular immunotherapies |
WO2024074977A1 (en) | 2022-10-04 | 2024-04-11 | Pfizer Inc. | Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds |
WO2024084364A1 (en) | 2022-10-18 | 2024-04-25 | Pfizer Inc. | Compounds for the treatment of cancer |
WO2024105563A1 (en) | 2022-11-16 | 2024-05-23 | Pfizer Inc. | Substituted bicyclic pyridone derivatives |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US191293A (en) | 1877-05-29 | Improvement in car wheels and axles | ||
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
AU634186B2 (en) | 1988-11-11 | 1993-02-18 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
SG48759A1 (en) | 1990-01-12 | 2002-07-23 | Abgenix Inc | Generation of xenogenic antibodies |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
DK0616640T3 (da) | 1991-12-02 | 2004-12-20 | Medical Res Council | Fremstilling af anti-selv antistoffer fra repertoirer af antistofsegmenter og fremvist på fag |
DE69233782D1 (de) | 1991-12-02 | 2010-05-20 | Medical Res Council | Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken |
US6765087B1 (en) | 1992-08-21 | 2004-07-20 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
DK0698097T3 (da) | 1993-04-29 | 2001-10-08 | Unilever Nv | Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde |
US5625825A (en) | 1993-10-21 | 1997-04-29 | Lsi Logic Corporation | Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network |
US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
EP1060247B2 (en) * | 1998-02-24 | 2011-10-26 | Sisters of Providence in Oregon | Ox-40 receptor binding agent for use in methods for enhancing tumour antigen-specific immune response |
KR100856446B1 (ko) | 1998-12-23 | 2008-09-04 | 화이자 인크. | Ctla-4에 대한 인간 단일클론 항체 |
CA2380813A1 (en) | 1999-07-29 | 2001-02-08 | Medarex, Inc. | Human monoclonal antibodies to her2/neu |
CA2430013C (en) | 2000-11-30 | 2011-11-22 | Medarex, Inc. | Transgenic transchromosomal rodents for making human antibodies |
PT1399483E (pt) | 2001-01-05 | 2010-07-20 | Pfizer | Anticorpos contra o receptor do factor i de crescimento tipo insulina |
KR100983997B1 (ko) | 2001-01-09 | 2010-09-28 | 메르크 파텐트 게엠베하 | 수용체 타이로신 키나아제 저해제 및 혈관형성 저해제를 사용하는 병용 요법 |
DK1399484T3 (da) | 2001-06-28 | 2010-11-08 | Domantis Ltd | Dobbelt-specifik ligand og anvendelse af denne |
WO2004058821A2 (en) | 2002-12-27 | 2004-07-15 | Domantis Limited | Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand |
AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
ATE395413T1 (de) | 2001-12-03 | 2008-05-15 | Amgen Fremont Inc | Antikörperkategorisierung auf der grundlage von bindungseigenschaften |
ES2295639T3 (es) * | 2002-06-13 | 2008-04-16 | Crucell Holland B.V. | Agonistas del receptor ox40=(=cd134) y uso terapeutico descripcion. |
ATE328906T1 (de) | 2002-06-28 | 2006-06-15 | Domantis Ltd | Dual-specifische liganden mit erhöhter halbwertszeit |
EP2357237A1 (en) | 2003-05-14 | 2011-08-17 | Domantis Limited | A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire |
ATE414106T1 (de) | 2003-06-30 | 2008-11-15 | Domantis Ltd | Pegylierte single-domain-antikörper (dab) |
ES2537163T3 (es) * | 2003-12-10 | 2015-06-03 | E. R. Squibb & Sons, L.L.C. | Anticuerpos de IP-10 y sus usos |
JP2008516586A (ja) * | 2004-09-30 | 2008-05-22 | メダレックス インコーポレーティッド | Fcγ受容体II(CD32)に対するヒトモノクローナル抗体 |
CN101072578A (zh) * | 2004-10-29 | 2007-11-14 | 南加州大学 | 用共刺激分子的联合癌症免疫疗法 |
WO2006055697A2 (en) | 2004-11-17 | 2006-05-26 | Board Of Regents, The University Of Texas System | Cancer immunotherapy incorporating p53 |
EP1844073A1 (en) | 2005-01-31 | 2007-10-17 | Ablynx N.V. | Method for generating variable domain sequences of heavy chain antibodies |
US7189097B2 (en) | 2005-02-11 | 2007-03-13 | Winchester Electronics Corporation | Snap lock connector |
US20080194596A1 (en) | 2005-06-03 | 2008-08-14 | Frizer Inc. | Therapeutic Combination Including a Selective Erbb2 Inhibitor |
JP2006345852A (ja) * | 2005-06-16 | 2006-12-28 | Virxsys Corp | 抗体複合体 |
EP1951242A2 (en) | 2005-11-22 | 2008-08-06 | Incyte Corporation | Combination therapy for the treatment of cancer |
TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類cd134(ox40)之人類單株抗體及其製造及使用方法 |
EP1973576B1 (en) | 2005-11-28 | 2019-05-15 | Genmab A/S | Recombinant monovalent antibodies and methods for production thereof |
ES2526887T3 (es) * | 2007-12-14 | 2015-01-16 | Bristol-Myers Squibb Company | Método para producir moléculas de unión al receptor OX40 humano |
-
2008
- 2008-12-11 ES ES12195976.1T patent/ES2526887T3/es active Active
- 2008-12-11 RU RU2010129045/10A patent/RU2010129045A/ru not_active Application Discontinuation
- 2008-12-11 DK DK14191564.5T patent/DK2851374T3/da active
- 2008-12-11 DK DK08862558.7T patent/DK2242771T3/da active
- 2008-12-11 MX MX2010006466A patent/MX2010006466A/es active IP Right Grant
- 2008-12-11 PT PT88625587T patent/PT2242771E/pt unknown
- 2008-12-11 SG SG10201604770VA patent/SG10201604770VA/en unknown
- 2008-12-11 EP EP12195976.1A patent/EP2594590B1/en active Active
- 2008-12-11 SI SI200831009T patent/SI2242771T1/sl unknown
- 2008-12-11 CA CA2707773A patent/CA2707773C/en active Active
- 2008-12-11 PL PL12195976T patent/PL2594590T3/pl unknown
- 2008-12-11 SI SI200831346T patent/SI2594590T1/sl unknown
- 2008-12-11 KR KR1020157013715A patent/KR20150061041A/ko not_active Application Discontinuation
- 2008-12-11 DK DK12195976.1T patent/DK2594590T3/da active
- 2008-12-11 CN CN200880120734.6A patent/CN101918447B/zh active Active
- 2008-12-11 ES ES08862558T patent/ES2425269T3/es active Active
- 2008-12-11 AU AU2008338591A patent/AU2008338591B8/en active Active
- 2008-12-11 WO PCT/US2008/086417 patent/WO2009079335A1/en active Application Filing
- 2008-12-11 PE PE2008002051A patent/PE20091269A1/es not_active Application Discontinuation
- 2008-12-11 EP EP17162625.2A patent/EP3239178A1/en not_active Ceased
- 2008-12-11 US US12/332,944 patent/US7960515B2/en active Active
- 2008-12-11 HU HUE14191564A patent/HUE032735T2/en unknown
- 2008-12-11 KR KR1020107015527A patent/KR101577843B1/ko active IP Right Grant
- 2008-12-11 SI SI200831814T patent/SI2851374T1/sl unknown
- 2008-12-11 BR BRPI0820875-1A patent/BRPI0820875B1/pt active IP Right Grant
- 2008-12-11 JP JP2010538157A patent/JP5761997B2/ja active Active
- 2008-12-11 EP EP14191564.5A patent/EP2851374B1/en active Active
- 2008-12-11 ES ES14191564.5T patent/ES2628093T3/es active Active
- 2008-12-11 PT PT121959761T patent/PT2594590E/pt unknown
- 2008-12-11 PL PL08862558T patent/PL2242771T3/pl unknown
- 2008-12-11 CA CA2949772A patent/CA2949772A1/en not_active Abandoned
- 2008-12-11 SG SG2012092201A patent/SG186656A1/en unknown
- 2008-12-11 PT PT141915645T patent/PT2851374T/pt unknown
- 2008-12-11 EP EP08862558.7A patent/EP2242771B1/en active Active
- 2008-12-12 AR ARP080105418A patent/AR069681A1/es active IP Right Grant
- 2008-12-12 TW TW097148544A patent/TW200932268A/zh unknown
- 2008-12-12 CL CL2008003706A patent/CL2008003706A1/es unknown
- 2008-12-12 PA PA20088807601A patent/PA8807601A1/es unknown
- 2008-12-15 UY UY31533A patent/UY31533A1/es active IP Right Grant
-
2010
- 2010-05-20 ZA ZA2010/03579A patent/ZA201003579B/en unknown
- 2010-06-10 IL IL206297A patent/IL206297A/en active IP Right Grant
- 2010-07-14 CO CO10086027A patent/CO6280541A2/es not_active Application Discontinuation
-
2011
- 2011-05-02 US US13/099,196 patent/US8236930B2/en active Active
-
2012
- 2012-05-17 US US13/474,466 patent/US9028824B2/en active Active
-
2014
- 2014-10-31 JP JP2014222800A patent/JP6248024B2/ja active Active
- 2014-12-08 HR HRP20141188A patent/HRP20141188T8/xx unknown
-
2015
- 2015-04-10 PH PH12015500806A patent/PH12015500806B1/en unknown
- 2015-04-22 US US14/692,948 patent/US9840562B2/en active Active
- 2015-06-29 IL IL239674A patent/IL239674A/en active IP Right Grant
-
2016
- 2016-05-26 IL IL245876A patent/IL245876A/en active IP Right Grant
-
2017
- 2017-01-20 JP JP2017008103A patent/JP6420379B2/ja active Active
- 2017-08-16 AR ARP170102289A patent/AR109355A2/es unknown
- 2017-11-08 US US15/807,351 patent/US10196452B2/en active Active
-
2018
- 2018-10-10 JP JP2018191343A patent/JP2019030313A/ja active Pending
-
2019
- 2019-01-11 US US16/245,816 patent/US20190135932A1/en not_active Abandoned
-
2021
- 2021-07-13 US US17/373,965 patent/US20220002428A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2242771T3 (da) | Bindingsmolekyler til den humane ox40-receptor | |
LTPA2018017I1 (lt) | Žmogaus CGRP receptorių rišantys antikūnai | |
LTPA2016001I1 (lt) | Antikūnai prieš žmogaus užprogramuotą mirties receptorių pd-1 | |
DK2307459T3 (da) | Notch1-receptorbindende midler og fremgangsmåder til anvendelse deraf | |
DK3424932T3 (da) | Bronophthalider til terapeutisk anvendelse | |
IS8842A (is) | Kjarnviðtaka bindimiðlar. | |
DK2358746T3 (da) | Bindingsproteiner til inhibering af vegf-a-receptorinteraktionen | |
DK2767265T3 (da) | Justerbart implantatsystem | |
DK2173407T3 (da) | Anordning til indgivelse af lægemiddel | |
ATE509022T1 (de) | Nikotin-acetylcholin-rezeptorsubtyp-selektive diazabicycloalkanamide | |
DK2189264T3 (da) | Ultrasonisk indretning til at forme mikroplastdele | |
DE602008006709D1 (de) | Funduskamera | |
DK2205558T3 (da) | Substituterede n-phenylpyrrolidinylmethylpyrrolidinamider og terapeutisk anvendelse deraf som histamin-h3- receptormodulatorer | |
BRPI0820410A2 (pt) | Lactans substituídos terapêuticos | |
BRPI0809653A2 (pt) | Formulações líquidas de manoproteína | |
BRPI0912998A2 (pt) | métodos de tratamento que utilizam proteínas de ligação do receptor para a interleucina-21 | |
DK2248392T3 (da) | Håndholdt anordning til hudbehandling | |
DE602007008589D1 (de) | Pyridooxazepin-progesteronrezeptor-modulatoren | |
PL2851374T3 (pl) | Cząsteczki wiążące się z ludzkim receptorem ox40 | |
FI20075143A0 (fi) | Laite potilaan lämmittämiseksi | |
ES1065210Y (es) | Cultivador de intercepas para viñedos | |
TH97253B (th) | อุปกรณ์ช่วยจัดกระดูกสันหลัง | |
NL2002090C (nl) | Bindinrichting. | |
TH98274B (th) | สารปรับคุมแคนนาบินอยด์รีเซปเตอร์ | |
FI20070676L (fi) | Puristuslaite |